See more : Addex Therapeutics Ltd (ADXN) Income Statement Analysis – Financial Results
Complete financial analysis of Cipla Limited (CIPLA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cipla Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- BorgWarner Inc. (BWA) Income Statement Analysis – Financial Results
- Goodyear (Thailand) Public Company Limited (GYT.BK) Income Statement Analysis – Financial Results
- Green Visor Financial Technology Acquisition Corp. I (GVCIU) Income Statement Analysis – Financial Results
- Shanghai Yanpu Metal Products Co.,Ltd (605128.SS) Income Statement Analysis – Financial Results
- Acanthe Développement (ACAN.PA) Income Statement Analysis – Financial Results
Cipla Limited (CIPLA.NS)
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 257.74B | 224.73B | 216.33B | 189.97B | 167.04B | 160.16B | 147.91B | 140.70B | 136.63B | 113.45B | 101.00B | 82.79B | 649.00M | 61.30B | 53.60B | 49.61B | 40.10B | 34.38B | 28.97B | 21.81B | 18.42B |
| Cost of Revenue | 90.44B | 82.52B | 92.30B | 80.20B | 66.09B | 63.61B | 60.54B | 58.91B | 56.18B | 45.82B | 42.14B | 32.64B | 30.35B | 27.47B | 26.84B | 25.87B | 22.86B | 18.99B | 15.71B | 12.25B | 10.99B |
| Gross Profit | 167.30B | 142.21B | 124.03B | 109.76B | 100.94B | 96.55B | 87.37B | 81.78B | 80.45B | 67.63B | 58.87B | 50.16B | -29.70B | 33.83B | 26.75B | 23.74B | 17.25B | 15.39B | 13.26B | 9.56B | 7.43B |
| Gross Profit Ratio | 64.91% | 63.28% | 57.33% | 57.78% | 60.43% | 60.28% | 59.07% | 58.13% | 58.88% | 59.61% | 58.28% | 60.58% | -4,575.65% | 55.19% | 49.92% | 47.86% | 43.00% | 44.77% | 45.77% | 43.84% | 40.33% |
| Research & Development | 4.30B | 3.85B | 2.66B | 1.33B | 3.55B | 3.57B | 2.69B | 2.80B | 2.19B | 1.12B | 1.06B | 432.10M | 363.00M | 2.60B | 2.51B | 2.36B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.59B | 9.28B | 8.12B | 7.05B | 7.82B | 5.79B | 5.26B | 4.51B | 3.65B | 3.19B | 2.64B | 2.98B | 2.12B | 14.96B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 17.25B | 16.94B | 16.70B | 12.99B | 12.52B | 12.81B | 10.83B | 10.09B | 8.19B | 7.39B | 6.09B | 4.66B | 4.68B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.90B | 26.22B | 24.82B | 20.04B | 20.34B | 18.60B | 16.09B | 14.60B | 11.84B | 10.58B | 8.73B | 7.64B | 6.80B | 14.96B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1.13B | 4.75B | 538.60M | 338.10M | 293.50M | 347.60M | 49.74B | 152.20M | 161.90M | 150.70M | 240.30M | 287.70M | 251.80M | 4.47B | 11.71B | 12.42B | 8.87B | 7.25B | 6.05B | 4.34B | 3.29B |
| Operating Expenses | 59.22B | 103.66B | 88.33B | 77.26B | 79.84B | 76.20B | 68.51B | 65.35B | 60.73B | 49.31B | 41.02B | 29.25B | 25.00B | 22.03B | 14.21B | 14.77B | 8.87B | 7.25B | 6.05B | 4.34B | 3.29B |
| Cost & Expenses | 149.66B | 186.18B | 180.62B | 157.46B | 145.93B | 139.81B | 129.06B | 124.26B | 116.91B | 95.13B | 83.16B | 61.88B | 55.34B | 49.51B | 41.05B | 40.64B | 31.72B | 26.24B | 21.76B | 16.59B | 14.28B |
| Interest Income | 2.08B | 1.62B | 796.20M | 472.60M | 676.70M | 598.60M | 296.40M | 124.80M | 98.50M | 98.10M | 171.10M | 44.10M | 84.10M | 71.30M | 0.00 | 192.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 711.30M | 1.10B | 1.05B | 1.53B | 1.89B | 1.64B | 1.09B | 876.80M | 696.90M | 712.70M | 557.10M | 275.70M | 238.40M | 173.20M | 229.50M | 522.30M | 0.00 | 69.50M | 114.20M | 0.00 | 0.00 |
| Depreciation & Amortization | 9.42B | 10.18B | 9.88B | 10.01B | 10.97B | 10.96B | 9.50B | 8.71B | 5.42B | 5.05B | 3.73B | 3.30B | 3.12B | 2.73B | 1.90B | 1.71B | 1.31B | 1.03B | 801.80M | 550.47M | 402.84M |
| EBITDA | 67.20B | 51.32B | 45.72B | 44.36B | 34.65B | 33.43B | 27.41B | 22.58B | 25.98B | 23.27B | 23.98B | 24.60B | 17.98B | 14.34B | 15.16B | 10.67B | 9.69B | 9.15B | 8.02B | 5.77B | 4.55B |
| EBITDA Ratio | 26.07% | 24.48% | 21.79% | 23.39% | 20.82% | 22.03% | 21.74% | 20.55% | 18.62% | 19.05% | 22.75% | 29.08% | 2,745.99% | 23.70% | 26.94% | 21.52% | 24.15% | 26.72% | 27.66% | 26.47% | 24.69% |
| Operating Income | 105.71B | 40.08B | 35.63B | 32.49B | 21.20B | 20.41B | 18.93B | 16.44B | 19.72B | 18.32B | 17.85B | 20.91B | -54.69B | 11.80B | 12.54B | 8.97B | 8.38B | 8.14B | 7.21B | 5.22B | 4.14B |
| Operating Income Ratio | 41.01% | 17.83% | 16.47% | 17.10% | 12.69% | 12.74% | 12.80% | 11.68% | 14.43% | 16.15% | 17.67% | 25.26% | -8,427.15% | 19.25% | 23.40% | 18.08% | 20.90% | 23.68% | 24.89% | 23.94% | 22.50% |
| Total Other Income/Expenses | -48.69B | -46.64B | -45.92B | -40.63B | 676.60M | 440.00M | -2.16B | -4.21B | -115.30M | -99.80M | -1.70B | 41.70M | -387.90M | -173.20M | 720.50M | -13.20M | 0.00 | -28.90M | -99.40M | -76.30M | -103.94M |
| Income Before Tax | 57.02B | 40.38B | 34.93B | 32.90B | 21.78B | 20.79B | 16.69B | 12.22B | 20.07B | 16.54B | 18.80B | 20.95B | 14.48B | 11.62B | 13.26B | 8.96B | 8.38B | 8.08B | 7.10B | 5.15B | 4.04B |
| Income Before Tax Ratio | 22.12% | 17.97% | 16.15% | 17.32% | 13.04% | 12.98% | 11.29% | 8.69% | 14.69% | 14.58% | 18.61% | 25.31% | 2,230.83% | 18.96% | 24.74% | 18.05% | 20.90% | 23.50% | 24.50% | 23.59% | 21.93% |
| Income Tax Expense | 15.47B | 12.03B | 9.34B | 8.89B | 6.31B | 5.70B | 2.50B | 1.80B | 4.40B | 4.00B | 4.63B | 5.44B | 3.07B | 1.95B | 2.44B | 1.25B | 1.37B | 1.40B | -1.02B | 1.05B | 877.50M |
| Net Income | 41.22B | 28.02B | 25.17B | 24.05B | 15.47B | 15.28B | 14.11B | 10.06B | 15.06B | 11.81B | 13.88B | 15.45B | 11.44B | 9.67B | 10.83B | 7.71B | 7.01B | 6.68B | 6.08B | 4.10B | 3.07B |
| Net Income Ratio | 15.99% | 12.47% | 11.63% | 12.66% | 9.26% | 9.54% | 9.54% | 7.15% | 11.02% | 10.41% | 13.75% | 18.66% | 1,763.08% | 15.78% | 20.20% | 15.54% | 17.48% | 19.43% | 20.97% | 18.78% | 16.65% |
| EPS | 51.05 | 34.72 | 31.20 | 29.82 | 19.19 | 18.97 | 17.53 | 12.52 | 16.93 | 14.71 | 17.29 | 19.24 | 14.25 | 12.32 | 13.70 | 9.92 | 9.02 | 8.61 | 8.10 | 5.46 | 3.94 |
| EPS Diluted | 51.01 | 34.69 | 31.17 | 29.79 | 19.16 | 18.93 | 17.50 | 12.50 | 16.89 | 14.66 | 17.27 | 19.24 | 14.25 | 12.32 | 13.70 | 9.92 | 9.02 | 8.61 | 8.10 | 5.46 | 3.94 |
| Weighted Avg Shares Out | 807.35M | 807.01M | 806.67M | 806.36M | 806.02M | 805.36M | 804.77M | 803.98M | 803.14M | 802.93M | 802.92M | 802.92M | 802.92M | 802.92M | 790.14M | 777.29M | 778.29M | 777.29M | 775.93M | 749.68M | 749.65M |
| Weighted Avg Shares Out (Dil) | 808.00M | 807.63M | 807.44M | 807.30M | 807.08M | 806.83M | 806.08M | 805.32M | 805.42M | 805.59M | 804.08M | 802.92M | 802.92M | 802.92M | 790.14M | 777.29M | 778.29M | 777.29M | 775.93M | 749.68M | 749.65M |
Source: https://incomestatements.info
Category: Stock Reports